Hyperfine, Inc. (NASDAQ:HYPR) Stock Has Consensus Price Target of $2.03

Key Points

• Analysts have a consensus “Hold” rating on Hyperfine, with three buys, one hold and one sell among five firms. The average 12-month price target is $2.03, compared with the stock’s recent opening price of $0.87.
• Hyperfine reported a quarterly loss of $0.09 per share, in line with estimates, while revenue of $3.90 million fell short of the $4.13 million consensus forecast. Analysts expect a full-year loss of approximately $0.34 per share.
• The medical technology company develops the Swoop Portable MR Imaging System, a low-field, AI-enabled MRI platform designed for bedside brain imaging in hospitals and intensive-care settings.

Hyperfine, Inc. (NASDAQ:HYPR - Get Free Report) has been given a consensus recommendation of "Hold" by the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $2.03.

Several research firms have issued reports on HYPR. B. Riley Financial reaffirmed a "buy" rating and set a $1.60 price target (down from $2.00) on shares of Hyperfine in a research report on Monday, August 10th. BTIG Research restated a "buy" rating and set a $2.00 price objective on shares of Hyperfine in a research note on Tuesday, September 22nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Hyperfine in a research note on Friday, July 17th.

Hyperfine Stock Performance

Shares of Hyperfine stock opened at $0.87 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.15 and a quick ratio of 5.45. The firm has a market cap of $92.26 million, a price-to-earnings ratio of -2.29 and a beta of 1.45. The stock's 50-day moving average is $0.86 and its 200-day moving average is $1.16. Hyperfine has a one year low of $0.75 and a one year high of $2.22.

Hyperfine (NASDAQ:HYPR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The business had revenue of $3.90 million for the quarter, compared to the consensus estimate of $4.13 million. Hyperfine had a negative return on equity of 97.88% and a negative net margin of 210.75%. Equities analysts predict that Hyperfine will post -0.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new position in shares of Hyperfine in the second quarter valued at $419,000. Renaissance Technologies LLC grew its position in shares of Hyperfine by 100.2% in the first quarter. Renaissance Technologies LLC now owns 730,233 shares of the company's stock valued at $789,000 after purchasing an additional 365,490 shares during the last quarter. Walleye Capital LLC grew its position in shares of Hyperfine by 3.4% in the first quarter. Walleye Capital LLC now owns 223,988 shares of the company's stock valued at $242,000 after purchasing an additional 7,330 shares during the last quarter. Finally, Catalio Capital Management LP increased its stake in shares of Hyperfine by 92.8% during the fourth quarter. Catalio Capital Management LP now owns 1,320,041 shares of the company's stock worth $1,293,000 after purchasing an additional 635,500 shares during the period. 15.03% of the stock is owned by institutional investors and hedge funds.

Hyperfine Company Profile

Hyperfine, Inc NASDAQ: HYPR is a medical technology company focused on making magnetic resonance imaging (MRI) more accessible and convenient. Its flagship product, the Swoop Portable MR Imaging System, is designed to provide brain imaging at or near the patient's bedside rather than requiring transport to a traditional MRI suite.

The Swoop system uses a low-field magnetic resonance platform, artificial intelligence-enabled image processing and a mobile design to support neuroimaging in settings such as hospitals, intensive care units and other clinical environments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.